Kuros Biosciences Statistics
Want to see CH:KURN full AI Analyst Report?
Kuros Biosciences (KURN) Stock Statistics & Valuation Metrics
Total Valuation
Kuros Biosciences has a market cap or net worth of CHF 779.80M. The enterprise value is CHF 776.03M.
- Market Cap
- CHF 779.80M
- Enterprise Value
- CHF 776.03M
Share Statistics
Kuros Biosciences has 39,826,588 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 39,826,588
- Owned by Insiders
- ―
- Owned by Institutions
- 2.76%
Financial Efficiency
Kuros Biosciences’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 4.80%.
- Return on Equity (ROE)
- 0.03
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- 4.80%
- Return on Capital Employed (ROCE)
- 0.10
- Revenue Per Employee
- 569.48K
- Profits Per Employee
- 9,946.338
- Employee Count
- 213
- Asset Turnover
- 1.13
- Inventory Turnover
- 0.98
Valuation Ratios
The current PE Ratio of Kuros Biosciences is 111.05. Kuros Biosciences’s PEG ratio is 0.13.
- PE Ratio
- 111.05
- PS Ratio
- 5.76
- PB Ratio
- 11.02
- Price to FCF
- -120.84
- Price to Operating Cash Flow
- -2707.70
- PEG Ratio
- 0.13
Income Statement
In the last 12 months, Kuros Biosciences had revenue of 121.30M and earned 2.12M in profits. Earnings per share was 0.06.
- Revenue
- 121.30M
- Gross Profit
- 104.79M
- Operating Income
- 7.33M
- Pretax Income
- 4.16M
- Net Income
- 2.12M
- EBITDA
- 10.01M
- Earnings Per Share (EPS)
- 0.06
Cash Flow
In the last 12 months, operating cash flow was -292.91K and capital expenditures -6.32M, giving a free cash flow of -6.61M billion.
- Operating Cash Flow
- -292.91K
- Free Cash Flow
- -6.61M
- Free Cash Flow per Share
- -0.17
Dividends & Yields
Kuros Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.84%
- Earnings Yield
- 0.92%
Stock Price Statistics
- Beta
- 1.30
- 52-Week Price Change
- -25.67%
- 50-Day Moving Average
- 18.66
- 200-Day Moving Average
- 21.45
- Relative Strength Index (RSI)
- 53.05
- Average Volume (3m)
- 230.46K
Important Dates
Kuros Biosciences upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Mar 03, 2027
- Ex-Dividend Date
- ―
Financial Position
Kuros Biosciences as a current ratio of 1.96, with Debt / Equity ratio of 5.88%
- Current Ratio
- 1.96
- Quick Ratio
- 1.45
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -1.17
- Interest Coverage Ratio
- 24.04
Taxes
In the past 12 months, Kuros Biosciences has paid 2.12M in taxes.
- Income Tax
- 2.12M
- Effective Tax Rate
- 0.51
Enterprise Valuation
Kuros Biosciences EV to EBITDA ratio is 68.06, with an EV/FCF ratio of -118.91.
- EV to Sales
- 5.67
- EV to EBITDA
- 68.06
- EV to Free Cash Flow
- -118.91
- EV to Operating Cash Flow
- -2684.63
Balance Sheet
Kuros Biosciences has CHF 7.85M in cash and marketable securities with CHF 11.01M in debt, giving a net cash position of -CHF 3.16M billion.
- Cash & Marketable Securities
- CHF 7.85M
- Total Debt
- CHF 11.01M
- Net Cash
- -CHF 3.16M
- Net Cash Per Share
- -CHF 0.08
- Tangible Book Value Per Share
- CHF 1.03
Margins
Gross margin is 85.28%, with operating margin of 6.01%, and net profit margin of 5.13%.
- Gross Margin
- 85.28%
- Operating Margin
- 6.01%
- Pretax Margin
- 6.15%
- Net Profit Margin
- 5.13%
- EBITDA Margin
- 8.33%
- EBIT Margin
- 6.01%
Analyst Forecast
The average price target for Kuros Biosciences is CHF 33.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- CHF 33.00
- Price Target Upside
- 64.18% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 40.91%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- ―
- AI Score
- 63
